Long-Term Clinical Outcome of Intensity-Modulated Radiotherapy for Inoperable Non-Small Cell Lung Cancer: The MD Anderson Experience

医学 肺癌 肿瘤科 放射治疗 期限(时间) 结果(博弈论) 内科学 物理 数学 数理经济学 量子力学
作者
Zhi-Qin Jiang,Kunyu Yang,Ritsuko Komaki,Wei Xiong,Susan L. Tucker,Yan Zhuang,Mary K. Martel,S. Vedam,Peter Balter,Guangying Zhu,Daniel R. Gomez,Charles Lu,Radhe Mohan,James D. Cox,Zhongxing Liao
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:83 (1): 332-339 被引量:141
标识
DOI:10.1016/j.ijrobp.2011.06.1963
摘要

Purpose In 2007, we published our initial experience in treating inoperable non-small-cell lung cancer (NSCLC) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up. Methods and Materials Patients in this retrospective review were 165 patients who began definitive radiotherapy, with or without chemotherapy, for newly diagnosed, pathologically confirmed NSCLC to a dose of ≥60 Gy from 2005 to 2006. Early and late toxicities assessed included treatment-related pneumonitis (TRP), pulmonary fibrosis, esophagitis, and esophageal stricture, scored mainly according to the Common Terminology Criteria for Adverse Events 3.0. Other variables monitored were radiation-associated dermatitis and changes in body weight and Karnofsky performance status. The Kaplan-Meier method was used to compute survival and freedom from radiation-related acute and late toxicities as a function of time. Results Most patients (89%) had Stage III to IV disease. The median radiation dose was 66 Gy given in 33 fractions (range, 60–76 Gy, 1.8–2.3 Gy per fraction). Median overall survival time was 1.8 years; the 2-year and 3-year overall survival rates were 46% and 30%. Rates of Grade ≥3 maximum TRP (TRPmax) were 11% at 6 months and 14% at 12 months. At 18 months, 86% of patients had developed Grade ≥1 maximum pulmonary fibrosis (pulmonary fibrosismax) and 7% Grade ≥2 pulmonary fibrosismax. The median times to maximum esophagitis (esophagitismax) were 3 weeks (range, 1–13 weeks) for Grade 2 and 6 weeks (range, 3–13 weeks) for Grade 3. A higher percentage of patients who experienced Grade 3 esophagitismax later developed Grade 2 to 3 esophageal stricture. Conclusions In our experience, using IMRT to treat NSCLC leads to low rates of pulmonary and esophageal toxicity, and favorable clinical outcomes in terms of survival. In 2007, we published our initial experience in treating inoperable non-small-cell lung cancer (NSCLC) with intensity-modulated radiation therapy (IMRT). The current report is an update of that experience with long-term follow-up. Patients in this retrospective review were 165 patients who began definitive radiotherapy, with or without chemotherapy, for newly diagnosed, pathologically confirmed NSCLC to a dose of ≥60 Gy from 2005 to 2006. Early and late toxicities assessed included treatment-related pneumonitis (TRP), pulmonary fibrosis, esophagitis, and esophageal stricture, scored mainly according to the Common Terminology Criteria for Adverse Events 3.0. Other variables monitored were radiation-associated dermatitis and changes in body weight and Karnofsky performance status. The Kaplan-Meier method was used to compute survival and freedom from radiation-related acute and late toxicities as a function of time. Most patients (89%) had Stage III to IV disease. The median radiation dose was 66 Gy given in 33 fractions (range, 60–76 Gy, 1.8–2.3 Gy per fraction). Median overall survival time was 1.8 years; the 2-year and 3-year overall survival rates were 46% and 30%. Rates of Grade ≥3 maximum TRP (TRPmax) were 11% at 6 months and 14% at 12 months. At 18 months, 86% of patients had developed Grade ≥1 maximum pulmonary fibrosis (pulmonary fibrosismax) and 7% Grade ≥2 pulmonary fibrosismax. The median times to maximum esophagitis (esophagitismax) were 3 weeks (range, 1–13 weeks) for Grade 2 and 6 weeks (range, 3–13 weeks) for Grade 3. A higher percentage of patients who experienced Grade 3 esophagitismax later developed Grade 2 to 3 esophageal stricture. In our experience, using IMRT to treat NSCLC leads to low rates of pulmonary and esophageal toxicity, and favorable clinical outcomes in terms of survival.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
青衫完成签到 ,获得积分10
1秒前
JJ完成签到,获得积分10
3秒前
4秒前
小鱼医生完成签到 ,获得积分10
4秒前
JJ发布了新的文献求助10
5秒前
hannah发布了新的文献求助10
6秒前
灰灰喵完成签到 ,获得积分10
6秒前
执着新蕾完成签到,获得积分10
7秒前
蜀山刀客完成签到,获得积分10
8秒前
崔宁宁完成签到 ,获得积分0
11秒前
卓垚完成签到,获得积分10
13秒前
yar完成签到 ,获得积分10
16秒前
nancy应助hannah采纳,获得10
16秒前
碧蓝巧荷完成签到 ,获得积分10
17秒前
QYY完成签到,获得积分10
18秒前
风清扬应助自然白秋采纳,获得20
18秒前
小么完成签到 ,获得积分10
19秒前
美好凡柔完成签到 ,获得积分10
20秒前
进退须臾完成签到,获得积分10
20秒前
zyshao完成签到,获得积分10
25秒前
TG303完成签到,获得积分10
25秒前
干净盼山完成签到,获得积分10
29秒前
liujinjin完成签到,获得积分10
30秒前
smottom完成签到,获得积分0
30秒前
32秒前
maxyer完成签到,获得积分10
33秒前
rayzhanghl完成签到,获得积分10
34秒前
jintian完成签到 ,获得积分10
36秒前
单纯的醉柳完成签到 ,获得积分10
36秒前
善良的火完成签到 ,获得积分10
37秒前
胡楠完成签到,获得积分10
37秒前
乌云乌云快走开完成签到,获得积分10
38秒前
qqaeao完成签到,获得积分10
38秒前
韭菜盒子完成签到,获得积分20
39秒前
万事屋完成签到 ,获得积分10
43秒前
量子星尘发布了新的文献求助10
43秒前
44秒前
wdccx完成签到,获得积分10
44秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
A new approach to the extrapolation of accelerated life test data 1000
Coking simulation aids on-stream time 450
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
Novel Preparation of Chitin Nanocrystals by H2SO4 and H3PO4 Hydrolysis Followed by High-Pressure Water Jet Treatments 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4015670
求助须知:如何正确求助?哪些是违规求助? 3555644
关于积分的说明 11318192
捐赠科研通 3288842
什么是DOI,文献DOI怎么找? 1812284
邀请新用户注册赠送积分活动 887882
科研通“疑难数据库(出版商)”最低求助积分说明 812015